Recent data showed that IP3R3 function was drastically impaired by epidermal growth factor receptor (EGFR) and tyrosine-protein kinase (MET) inhibitors in oncogene-driven non-small cell lung cancer (NSCLC), thus raising intriguing questions regarding the possibility of targeting upstream or downstream regulator or effector proteins of IP3R3 to treat metastatic cancer patients, particularly those with NSCLC [29]. This evidence concerns the gene EGFR and metastatic malignant neoplasm.